Loading…

Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021

Dengue is a vectorborne infectious disease caused by dengue viruses (DENVs), which are predominantly transmitted by Aedes aegypti and Aedes albopictus mosquitos. Dengue is caused by four closely related viruses (DENV-1–4), and a person can be infected with each serotype for a total of four infection...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Recommendations and reports 2021-12, Vol.70 (6), p.1-15
Main Authors: Paz-Bailey, Gabriela, Adams, Laura, Wong, Joshua M., Poehling, Katherine A., Chen, Wilbur H., McNally, Veronica, Atmar, Robert L., Waterman, Stephen H.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c439t-59efedca3c1d92de8d60b5888fe9067046559564ae73b8510caef9a3fe6f3c2e3
cites cdi_FETCH-LOGICAL-c439t-59efedca3c1d92de8d60b5888fe9067046559564ae73b8510caef9a3fe6f3c2e3
container_end_page 15
container_issue 6
container_start_page 1
container_title MMWR. Recommendations and reports
container_volume 70
creator Paz-Bailey, Gabriela
Adams, Laura
Wong, Joshua M.
Poehling, Katherine A.
Chen, Wilbur H.
McNally, Veronica
Atmar, Robert L.
Waterman, Stephen H.
description Dengue is a vectorborne infectious disease caused by dengue viruses (DENVs), which are predominantly transmitted by Aedes aegypti and Aedes albopictus mosquitos. Dengue is caused by four closely related viruses (DENV-1–4), and a person can be infected with each serotype for a total of four infections during their lifetime. Areas where dengue is endemic in the United States and its territories and freely associated states include Puerto Rico, American Samoa, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau. This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. Dengvaxia was licensed by the Food and Drug Administration for use among children and adolescents aged 9–16 years (referred to in this report as children). ACIP recommends vaccination with Dengvaxia for children aged 9–16 having evidence of a previous dengue infection and living in areas where dengue is endemic. Evidence of previous dengue infection, such as detection of anti-DENV immunoglobulin G with a highly specific serodiagnostic test, will be required for eligible children before vaccination.
doi_str_mv 10.15585/MMWR.RR7006A1
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8694708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>27286883</jstor_id><sourcerecordid>27286883</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-59efedca3c1d92de8d60b5888fe9067046559564ae73b8510caef9a3fe6f3c2e3</originalsourceid><addsrcrecordid>eNpdkEtLAzEURoMoVqsu3Sniys3UZPLeCKU-oUUoPpYhzdypUzozNZlR_PdGW4u6uhfuyeHLh9AhwT3CueLno9HzuDceS4xFn2ygHcIZT5TAZDPumMuEayU7aDeEGcaYMa23UYcyLRVncgcdXEI1beHkyTpXVLCHtnI7D7C_ml30eH31MLhNhvc3d4P-MHGM6iY6IYfMWepIptMMVCbwhCulctBYSMwE55oLZkHSieIEOwu5tjQHkVOXAu2ii6V30U7KaIKq8XZuFr4orf8wtS3M30tVvJhp_WaU0ExiFQWnK4GvX1sIjfGwqH0TTCqxlETEMBE6-weVRXAwn9sK6jaigohUyRg2or0l6nwdgod8nYVg8920Kct3b7z_atqS-OD49w_W-E-1EThaArPQ1H59T2WqYjhKPwHMTYLE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2707716888</pqid></control><display><type>article</type><title>Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021</title><source>Open Access: PubMed Central</source><creator>Paz-Bailey, Gabriela ; Adams, Laura ; Wong, Joshua M. ; Poehling, Katherine A. ; Chen, Wilbur H. ; McNally, Veronica ; Atmar, Robert L. ; Waterman, Stephen H.</creator><creatorcontrib>Paz-Bailey, Gabriela ; Adams, Laura ; Wong, Joshua M. ; Poehling, Katherine A. ; Chen, Wilbur H. ; McNally, Veronica ; Atmar, Robert L. ; Waterman, Stephen H.</creatorcontrib><description>Dengue is a vectorborne infectious disease caused by dengue viruses (DENVs), which are predominantly transmitted by Aedes aegypti and Aedes albopictus mosquitos. Dengue is caused by four closely related viruses (DENV-1–4), and a person can be infected with each serotype for a total of four infections during their lifetime. Areas where dengue is endemic in the United States and its territories and freely associated states include Puerto Rico, American Samoa, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau. This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. Dengvaxia was licensed by the Food and Drug Administration for use among children and adolescents aged 9–16 years (referred to in this report as children). ACIP recommends vaccination with Dengvaxia for children aged 9–16 having evidence of a previous dengue infection and living in areas where dengue is endemic. Evidence of previous dengue infection, such as detection of anti-DENV immunoglobulin G with a highly specific serodiagnostic test, will be required for eligible children before vaccination.</description><identifier>ISSN: 1057-5987</identifier><identifier>EISSN: 1545-8601</identifier><identifier>DOI: 10.15585/MMWR.RR7006A1</identifier><identifier>PMID: 34978547</identifier><language>eng</language><publisher>United States: Centers for Disease Control &amp; Prevention (CDC)</publisher><subject>Antibodies ; Antigens ; Ascites ; Children ; Dengue fever ; Dengue hemorrhagic fever ; Disease transmission ; Fatalities ; IgG antibody ; Illnesses ; Immunization ; Immunoglobulin G ; Immunoglobulins ; Infections ; Infectious diseases ; Insecticides ; Islands ; Pesticides ; Recommendations and Reports ; Serology ; Vaccination ; Vaccines ; Vector-borne diseases ; Viruses ; Yellow fever ; Zika virus</subject><ispartof>MMWR. Recommendations and reports, 2021-12, Vol.70 (6), p.1-15</ispartof><rights>Published 2021. This article is a U.S. Government work and is in the public domain in the USA.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-59efedca3c1d92de8d60b5888fe9067046559564ae73b8510caef9a3fe6f3c2e3</citedby><cites>FETCH-LOGICAL-c439t-59efedca3c1d92de8d60b5888fe9067046559564ae73b8510caef9a3fe6f3c2e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694708/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694708/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34978547$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paz-Bailey, Gabriela</creatorcontrib><creatorcontrib>Adams, Laura</creatorcontrib><creatorcontrib>Wong, Joshua M.</creatorcontrib><creatorcontrib>Poehling, Katherine A.</creatorcontrib><creatorcontrib>Chen, Wilbur H.</creatorcontrib><creatorcontrib>McNally, Veronica</creatorcontrib><creatorcontrib>Atmar, Robert L.</creatorcontrib><creatorcontrib>Waterman, Stephen H.</creatorcontrib><title>Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021</title><title>MMWR. Recommendations and reports</title><addtitle>MMWR Recomm Rep</addtitle><description>Dengue is a vectorborne infectious disease caused by dengue viruses (DENVs), which are predominantly transmitted by Aedes aegypti and Aedes albopictus mosquitos. Dengue is caused by four closely related viruses (DENV-1–4), and a person can be infected with each serotype for a total of four infections during their lifetime. Areas where dengue is endemic in the United States and its territories and freely associated states include Puerto Rico, American Samoa, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau. This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. Dengvaxia was licensed by the Food and Drug Administration for use among children and adolescents aged 9–16 years (referred to in this report as children). ACIP recommends vaccination with Dengvaxia for children aged 9–16 having evidence of a previous dengue infection and living in areas where dengue is endemic. Evidence of previous dengue infection, such as detection of anti-DENV immunoglobulin G with a highly specific serodiagnostic test, will be required for eligible children before vaccination.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Ascites</subject><subject>Children</subject><subject>Dengue fever</subject><subject>Dengue hemorrhagic fever</subject><subject>Disease transmission</subject><subject>Fatalities</subject><subject>IgG antibody</subject><subject>Illnesses</subject><subject>Immunization</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulins</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Insecticides</subject><subject>Islands</subject><subject>Pesticides</subject><subject>Recommendations and Reports</subject><subject>Serology</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vector-borne diseases</subject><subject>Viruses</subject><subject>Yellow fever</subject><subject>Zika virus</subject><issn>1057-5987</issn><issn>1545-8601</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkEtLAzEURoMoVqsu3Sniys3UZPLeCKU-oUUoPpYhzdypUzozNZlR_PdGW4u6uhfuyeHLh9AhwT3CueLno9HzuDceS4xFn2ygHcIZT5TAZDPumMuEayU7aDeEGcaYMa23UYcyLRVncgcdXEI1beHkyTpXVLCHtnI7D7C_ml30eH31MLhNhvc3d4P-MHGM6iY6IYfMWepIptMMVCbwhCulctBYSMwE55oLZkHSieIEOwu5tjQHkVOXAu2ii6V30U7KaIKq8XZuFr4orf8wtS3M30tVvJhp_WaU0ExiFQWnK4GvX1sIjfGwqH0TTCqxlETEMBE6-weVRXAwn9sK6jaigohUyRg2or0l6nwdgod8nYVg8920Kct3b7z_atqS-OD49w_W-E-1EThaArPQ1H59T2WqYjhKPwHMTYLE</recordid><startdate>20211217</startdate><enddate>20211217</enddate><creator>Paz-Bailey, Gabriela</creator><creator>Adams, Laura</creator><creator>Wong, Joshua M.</creator><creator>Poehling, Katherine A.</creator><creator>Chen, Wilbur H.</creator><creator>McNally, Veronica</creator><creator>Atmar, Robert L.</creator><creator>Waterman, Stephen H.</creator><general>Centers for Disease Control &amp; Prevention (CDC)</general><general>U.S. Center for Disease Control</general><general>Centers for Disease Control and Prevention</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>KB0</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYCSY</scope><scope>5PM</scope></search><sort><creationdate>20211217</creationdate><title>Dengue Vaccine</title><author>Paz-Bailey, Gabriela ; Adams, Laura ; Wong, Joshua M. ; Poehling, Katherine A. ; Chen, Wilbur H. ; McNally, Veronica ; Atmar, Robert L. ; Waterman, Stephen H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-59efedca3c1d92de8d60b5888fe9067046559564ae73b8510caef9a3fe6f3c2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Ascites</topic><topic>Children</topic><topic>Dengue fever</topic><topic>Dengue hemorrhagic fever</topic><topic>Disease transmission</topic><topic>Fatalities</topic><topic>IgG antibody</topic><topic>Illnesses</topic><topic>Immunization</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulins</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Insecticides</topic><topic>Islands</topic><topic>Pesticides</topic><topic>Recommendations and Reports</topic><topic>Serology</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vector-borne diseases</topic><topic>Viruses</topic><topic>Yellow fever</topic><topic>Zika virus</topic><toplevel>online_resources</toplevel><creatorcontrib>Paz-Bailey, Gabriela</creatorcontrib><creatorcontrib>Adams, Laura</creatorcontrib><creatorcontrib>Wong, Joshua M.</creatorcontrib><creatorcontrib>Poehling, Katherine A.</creatorcontrib><creatorcontrib>Chen, Wilbur H.</creatorcontrib><creatorcontrib>McNally, Veronica</creatorcontrib><creatorcontrib>Atmar, Robert L.</creatorcontrib><creatorcontrib>Waterman, Stephen H.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Environmental Science Collection</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>MMWR. Recommendations and reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paz-Bailey, Gabriela</au><au>Adams, Laura</au><au>Wong, Joshua M.</au><au>Poehling, Katherine A.</au><au>Chen, Wilbur H.</au><au>McNally, Veronica</au><au>Atmar, Robert L.</au><au>Waterman, Stephen H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021</atitle><jtitle>MMWR. Recommendations and reports</jtitle><addtitle>MMWR Recomm Rep</addtitle><date>2021-12-17</date><risdate>2021</risdate><volume>70</volume><issue>6</issue><spage>1</spage><epage>15</epage><pages>1-15</pages><issn>1057-5987</issn><eissn>1545-8601</eissn><abstract>Dengue is a vectorborne infectious disease caused by dengue viruses (DENVs), which are predominantly transmitted by Aedes aegypti and Aedes albopictus mosquitos. Dengue is caused by four closely related viruses (DENV-1–4), and a person can be infected with each serotype for a total of four infections during their lifetime. Areas where dengue is endemic in the United States and its territories and freely associated states include Puerto Rico, American Samoa, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau. This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. Dengvaxia was licensed by the Food and Drug Administration for use among children and adolescents aged 9–16 years (referred to in this report as children). ACIP recommends vaccination with Dengvaxia for children aged 9–16 having evidence of a previous dengue infection and living in areas where dengue is endemic. Evidence of previous dengue infection, such as detection of anti-DENV immunoglobulin G with a highly specific serodiagnostic test, will be required for eligible children before vaccination.</abstract><cop>United States</cop><pub>Centers for Disease Control &amp; Prevention (CDC)</pub><pmid>34978547</pmid><doi>10.15585/MMWR.RR7006A1</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1057-5987
ispartof MMWR. Recommendations and reports, 2021-12, Vol.70 (6), p.1-15
issn 1057-5987
1545-8601
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8694708
source Open Access: PubMed Central
subjects Antibodies
Antigens
Ascites
Children
Dengue fever
Dengue hemorrhagic fever
Disease transmission
Fatalities
IgG antibody
Illnesses
Immunization
Immunoglobulin G
Immunoglobulins
Infections
Infectious diseases
Insecticides
Islands
Pesticides
Recommendations and Reports
Serology
Vaccination
Vaccines
Vector-borne diseases
Viruses
Yellow fever
Zika virus
title Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T02%3A33%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dengue%20Vaccine:%20Recommendations%20of%20the%20Advisory%20Committee%20on%20Immunization%20Practices,%20United%20States,%202021&rft.jtitle=MMWR.%20Recommendations%20and%20reports&rft.au=Paz-Bailey,%20Gabriela&rft.date=2021-12-17&rft.volume=70&rft.issue=6&rft.spage=1&rft.epage=15&rft.pages=1-15&rft.issn=1057-5987&rft.eissn=1545-8601&rft_id=info:doi/10.15585/MMWR.RR7006A1&rft_dat=%3Cjstor_pubme%3E27286883%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c439t-59efedca3c1d92de8d60b5888fe9067046559564ae73b8510caef9a3fe6f3c2e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2707716888&rft_id=info:pmid/34978547&rft_jstor_id=27286883&rfr_iscdi=true